Your browser version may not work well with NCBI's Web applications. More information here...
1: Expert Opin Pharmacother. 2004 Aug;5(8):1701-10.Click here to read Links

Managing toxic shock syndrome with antibiotics.

Annane D, Clair B, Salomon J.

Intensive Care Unit Raymond Poincaré University Hospital, AP-HP, School of Medicine Paris Ile de France Ouest, University Versailles Saint Quentin en Yvelines, 104 Boulevard Raymond Poincaré, 92380 Garches, France. djillali.annane@rpc.ap-hop-paris.fr

Toxic shock syndrome (TSS) is a serious disorder with a worldwide prevalence of approximately 3/100,000 persons. TSS is mainly caused by Streptococcus pyogenes or Staphylococcus aureus. Thus, beta-lactam and lincosamides, such as clindamycin, are the first-line drugs. Yet, the mortality rate remains unacceptably high; highlighting the role of bacterial toxin-mediated activation of the inflammatory cascade in TSS pathogenesis. Further strategies should be targeted towards interfering with the interaction between bacterial toxins and host T cells. This paper aims to provide an overview of the epidemiology, pathomechanisms, and clinical presentation of TSS, and criteria for selecting drugs among available antibiotics.

PMID: 15264985 [PubMed - indexed for MEDLINE]

Patient Drug Information

  • Clindamycin (Cleocin® )

    Clindamycin is used to treat certain types of bacterial infections, including infections of the lungs, skin, blood, female reproductive organs, and internal organs. Clindamycin is in a class of medications called lincomy...

  • Source: AHFS Consumer Medication Information